EPIDAURUS Heart Trial Halted Due to Bleeding Risks
Researchers stopped the study early after finding stronger medication failed to prevent ischemic risks.
Updated on Oct. 6, 2026 in Heart Disease
Live Poll
Would you adjust your prescribed medication based on the results of a single medical study?
The EPIDAURUS trial has been terminated early after researchers found that combining potent P2Y12 inhibitors with direct oral anticoagulants failed to reduce ischemic risk. The study revealed that this experimental regimen significantly increased bleeding risks in patients with atrial fibrillation and acute coronary syndrome.
Why it matters
The findings indicate that intensified antiplatelet therapy may cause more harm than good for high-risk cardiac patients. By observing that bleeding events carry a twofold increase in subsequent ischemic complications, the trial underscores the danger of aggressive drug combinations.
The EPIDAURUS trial, which enrolled 602 patients, reported a win-loss ratio of 1.19 for its primary efficacy endpoint. Analysis showed a hazard ratio of 2.18 for ischemic complications in patients who experienced bleeding versus those who did not.
The players
European Society of Cardiology
The organization hosted the congress in Munich where the study results were discussed.
The details
Participants in the experimental group received a direct oral anticoagulant combined with either prasugrel or ticagrelor. This approach was tested against a control group receiving direct oral anticoagulants with clopidogrel and in-hospital aspirin, with results assessed via hierarchical testing at 6 weeks.
Timeline
6 weeks was the timeframe for the primary endpoint assessment.
6 months was the duration for the planned time-to-event analysis.
The Big Picture
The EPIDAURUS trial findings contradict the European Society of Cardiology guidelines for antiplatelet therapy by demonstrating that more potent inhibitors do not improve patient outcomes. This departure from standard practice highlights a critical need to re-evaluate how anticoagulants are combined with antiplatelet agents.
Patients currently taking dual or triple anti-thrombotic therapies should consult their cardiologists about potential bleeding risks identified in this study. The trial results emphasize that clinicians must balance ischemic protection against the significant danger of hemorrhagic complications.
The takeaway
Healthcare providers should carefully monitor patients on combination anticoagulant regimens for any signs of bleeding. Preventing hemorrhagic events is essential, as these occurrences directly correlate with a higher risk of subsequent ischemic complications.
Further reading
Learn more about the latest developments in cardiac care on the Heart Disease page.
Source note: This article includes information reported by Healio.
Live Poll
Would you adjust your prescribed medication based on the results of a single medical study?
